We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

TAVI May Hold Benefits Over Surgical Aortic Valve Replacement

By HospiMedica International staff writers
Posted on 28 Oct 2016
A new study suggests that patients with severe aortic stenosis may have more to gain from transfemoral transcatheter aortic valve implantation (TAVI) than surgical replacement.

Researchers at McMaster University (Hamilton, ON, Canada), Jagiellonian University (Krakow, Poland), and other institutions conducted a systematic review of four trials with 3,179 patients and a median follow-up of two years to compare TAVI and surgical replacement of an aortic valve (SAVR) in patients with severe aortic stenosis (most of whom older than 80 years of age) who were at low and intermediate risk of perioperative death (i.e., less than 8%). Two reviewers independently extracted data and assessed risk of bias for outcomes important to the patients, which were selected a priori.

The results revealed that over a median follow-up of two years, transfemoral TAVI was associated with better outcomes than SAVR in terms of mortality, stroke, acute kidney injury (AKI), and bleeding. Among the 1,578 patients undergoing TAVI there were an estimated 30 fewer deaths per 1,000 patients than among the 1,550 undergoing SAVR, while for stroke, AKI, and bleeding, there were 20, 53, and 252 fewer instances (respectively). The occurrence of new-onset atrial fibrillation (AF) was also reduced, with 178 fewer instances. The study was published on September 28, 2016, in BMJ.

“The benefits of transfemoral TAVI over SAVR, and the fact that it is less invasive, are likely to make it more compelling for older patients, such as those aged over 85 years. SAVR, however, performs better than transapical TAVI, which is of interest to patients who are not candidates for transfemoral TAVI,” concluded lead author Reed Siemieniuk, MD, of McMaster, and colleagues. “Younger patients, for whom valve longevity could be extremely important, may be more likely to choose SAVR.”

TAVI involves the percutaneous insertion of a catheter containing a replacement valve through the groin or chest; the new valve is pushed into the correct site, where the surgeon expands it into position. TAVI is an increasingly popular alternative to open surgery, as it does not require thoracotomy or a heart-lung machine. Guidelines recommend both TAVI and SAVR in patients in high surgical risk, but recommend SAVR over TAVI for lower risk patients. But despite this recommendation, half of the TAVI centers in Europe perform TAVI in intermediate risk patients, and 10% of centers do so in low risk patients.

Related Links:
McMaster University
Jagiellonian University


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Illuminated Retractor System
HandLite

Latest Surgical Techniques News

Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons

Next-Gen Computer Assisted Vacuum Thrombectomy Technology Rapidly Removes Blood Clots

Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices